Bipartisan bill has been ASN's top legislative priority since 2009
Congress is passing the Comprehensive Immunosuppressive Drug Coverage for Kidney Transplant Patients Act as part of priority year-end package.
This legislation extends Medicare coverage of live-saving immunosuppressive medications for kidney transplant patients for the life of the kidney transplant. Currently coverage is restricted to 36 months post transplant: patients who cannot obtain private coverage and are unable to afford the medications lose their transplanted kidney and return to dialysis. About 375 people annually are estimated to lose their kidney transplant because they cannot afford immunosuppressives.
Nephrologists will receive boosts in payments – especially in the rate for reimbursement for home dialysis – starting on January 1, 2021, according a final rule recently issued by the Centers for Medicare and Medicaid Services (CMS). The increases to nephrologists’ reimbursements were part of a multi-year push by ASN to increase the values incorporated in those reimbursement calculations.
Participating clinicians should begin the application process now.
The Centers for Medicare and Medicaid Services (CMS) has announced that it is accepting the impact of COVID-19 as a condition for applying for an Extreme and Uncontrollable Circumstances exemption in the Merit-based Incentive Payment System (MIPS).
For the 2020 performance year (PY), Medicare will be using its Extreme and Uncontrollable Circumstances policy to allow clinicians, groups, and virtual groups to submit an application requesting reweighting of one or more MIPS performance categories due to the current COVID-19 public health emergency. To provide additional support to clinicians, the agency is extending the extreme and uncontrollable circumstances application deadline for PY 2020 to Monday, February 1, 2021 at 8 p.m. ET.
Join ASN for New Approaches to Transform Outcomes for Kidney Disease and Heart Disease in Patients with Diabetes, a videoconference scheduled for Thursday, December 10, from 4:00 – 5:30 PM EST.
International clinical experts will review the latest guidelines for both kidney disease and cardiovascular disease, and discuss the most recent clinical trials and promising therapies, including the groundbreaking use of SGLT2 inhibitors to reduce morbidity and mortality. These are among the first new therapies demonstrated to help prevent the development of heart disease and reduce progression of kidney disease in people with T2DM.
Kidney research and treatment is undergoing tremendous, positive change. Part of that change is propelled by the cutting-edge work funded by KidneyCure. Over 24 years, ASN, and now KidneyCure, has awarded over $53 million to advance kidney health by funding studies of excellence. The researchers performing this work have propelled a sea change of advances that are helping create a world without kidney diseases.
Final rule applies new standards to organ procurement in the U.S.
The U.S. Department of Health and Human Services (HHS) today took action to increase donation rates and organ transplantation rates by applying new standards of accountability and transparency to the nation’s Organ Procurement Organizations (OPOs). HHS finalized the Organ Procurement Organizations Conditions for Coverage: Revisions to the Outcome Measure Requirements for Organ Procurement Organization rule that was proposed earlier this year by the Centers for Medicare and Medicaid Services (CMS).
The United States Renal Data System released its 2020 Annual Data Report, featuring the latest data accumulated through 2018. This report, funded by the National Institute of Diabetes and Digestive Kidney Diseases, provides an overview of the impact of kidney disease on the US population. The annual report developed by the USRDS serves as an invaluable resource for ASN and the kidney community in determining policy priorities and advocacy efforts. In addition to familiar findings health outcomes and health care spending related to kidney disease and kidney failure, the 2020 Annual Data Report reviews the impact of COVID-19 on kidney patients.
Nearly 50% of US nephrologists are graduates of international medical schools . These individuals provide critical care in our nation’s teaching hospitals and in areas facing critical physician shortages, fight the COVID-19 pandemic on the front lines, and conduct pioneering research in labs across the country.
The American Society of Nephrology (ASN) condemns baseless claims that physicians and hospitals are overcounting or inflating the number of deaths due to the COVID-19 pandemic. People with kidney failure are the most vulnerable patients to COVID-19 in the entire Medicare population.
On behalf of our society, I thank each one of you for your unwavering commitment to improving kidney health throughout the world. This first-ever Kidney Week Reimagined symbolizes many of the opportunities and challenges nephrology faces. Your participation during these unparalleled and supremely challenging times is so highly valued and greatly appreciated.